Camp4 Therapeutics Highlights Lead SYNGAP1 Program CMP-002, Targets H2 2026 Clinical Entry
CAMP has more than doubled off its 52-week low of $1.305.
Summary
Camp4 Therapeutics updated its corporate presentation, emphasizing its lead program CMP-002 for SYNGAP1-related disorder and targeting a Phase 1/2 clinical study in H2 2026, positioning it as the first potential disease-modifying therapy for this condition.
Key Events · Product Development and Regulatory · CAMP
-
Strategic Pipeline Repositioning
The company has refocused its pipeline to prioritize SYNGAP1 and has funded the program to accelerate its path to the clinic.
-
CMP-002 Clinical Advancement
The lead candidate, CMP-002, is expected to enter a global Phase 1/2 study for SYNGAP1-related disorder as early as the second half of 2026.
-
Compelling Preclinical Data
Preclinical studies showed CMP-002 restored SYNGAP protein levels and improved disease phenotypes in humanized mouse models, and achieved broad brain distribution and protein upregulation in non-human primates.
-
First-in-Clinic Potential
CMP-002 is positioned to be the first disease-modifying medicine in clinical development for SYNGAP1, addressing a significant unmet medical need for over 10,000 US patients.
Analysis · CAMP · Life Sciences
Camp4 Therapeutics provided a corporate presentation detailing its strategic focus on CMP-002 for SYNGAP1-related disorder, a rare CNS condition with significant unmet medical need. The company aims to be the first to bring a disease-modifying therapy to the clinic for SYNGAP1, with a Phase 1/2 study anticipated as early as the second half of 2026. Preclinical data presented in the filing demonstrated CMP-002's ability to restore SYNGAP protein levels and improve behavioral phenotypes in models, suggesting strong translational potential. This update signals a clear pipeline prioritization and a significant step towards clinical development for its lead asset.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 35.7% of the 1694 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CAMP was trading at $5.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $307.7M. The 52-week trading range was $1.31 to $7.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.